About AMED Greetings from the president
“Our mission is to fast-track medical research and development.”
As medicine continues to advance at a remarkable rate, the development of new approaches to diagnostics and therapeutics to contribute to human health is vital. Under the growing weight of public expectation, we must continually face new challenges while trying to solve public health problems.
AMED was established in April 2015 to catalyze the process of medical innovation and overcome the barriers between sectors, connecting talented individuals to accelerate medical research and development.
In just three years, we have made significant gains in the fight against many diseases.
As part of the Initiative on Rare and Undiagnosed Diseases (IRUD), genetic analysis systems are more accessible than ever. This is thanks in part to the data sharing among physician scientists in Japan, which was pioneered by AMED. Through IRUD and the study of genetic analysis, 12 new diseases have also been discovered. More than 800 undiagnosed patients who suffered from diagnostic odyssey over many years were diagnosed within 6 months after their registration to the program. IRUD is now contributing to several case matching between Japanese and foreign patients, as AMED empowers global networks for data sharing.
In addition, we are in constant pursuit to solve Antimicrobial Resistance (AMR) ? an issue that poses significant threat to the world. The Japan Nosocomial Infections Surveillance (JANIS) program, which facilitates AMR data sharing between hospitals, will soon be introduced to Southeast Asian countries.
Furthermore, as Japan moves towards a superaging society, we made it our mission to build up a nationwide registry to assist with and contribute to dementia research and drug development.
AMED is also interested in reforming and galvanizing the funding systems. Beginning last year, we initiated Cyclic Innovation for Clinical Empowerment (CiCLE), a large-scale program in pursuit of greater medical innovation that fosters human resources. Under a collaborative effort between industry and academia, the program will run for a maximum of 10 years and provide participants the opportunity to develop into talented young leaders ? those who can help us progress into the future.
While our progress is encouraging, we understand the challenges we face cannot be overcome without global collaboration. To date, we have entered into Memorandum of Cooperation agreements with several of our counterparts: NIH in the U.S., MRC in the U.K., A*STAR in Singapore, SEIDI in Spain and the Ministry of Health in Lithuania. We have also established offices in the U.S., U.K. and Singapore to further reinforce our relationships.
Many challenges lie ahead as we work to improve health in Japan and around the world. However, through close cooperation with the global medical community, we can deliver the best medicine and change lives for the better.
Makoto Suematsu, M.D., Ph.D.
Last updated 2018.6.15